Mineralization and the Role of Matrixphosphoglycoprotein

基质磷酸糖蛋白的矿化和作用

基本信息

  • 批准号:
    7150740
  • 负责人:
  • 金额:
    $ 2.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-05-01 至 2006-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): X-linked hypophosphatemic rickets (HYP) is associated with severe defects in renal phosphate handling, vitamin D metabolism and mineralization. Understanding the pathophysiology of bone-mineral/renal loss disorders is prerequisite to effective treatment of HYP, periodontal disease, tumor induced osteomalacia, renal-stones, osteoporosis, ectopic-calcifications and renal dysfunction. We have substantive preliminary data that supports the hypothesis that mineralization in teeth and bone is regulated by a protein-protein interaction between MEPE (a matrix extracellular phosphoglycoprotein markedly elevated in HYP) and PHEX (a Zn-metalloendopeptidase defective in HYP). The MEPE-PHEX protein-protein interaction protects MEPE from proteolytic cleavage by proteases markedly elevated in HYP (notably cathepsin B). Osteoblast and odontoblast secreted-MEPE in the absence of PHEX is proteolytically cleaved, releasing a phosphorylated, acidic-aspartate-serine-rich, COOH-terminal MEPE-fragment (ASARM-peptide). The ASARM-peptide (2 kDa) is remarkably resistant to a vast array of proteases resulting in increased levels in Hyp. The ASARM-peptide inhibits mineralization and is a negative modulator of normal mineralization and elevated ASARM-peptide is wholly or in part responsible for the mineralization defects in HYP. This proposal will specifically focus on the role of MEPE and ASARM-peptides in mineralization in disease and health. Our specific aims will be: 1. Structural characterization and quantification of MEPE ASARM-peptide(s) in-vitro and in-vivo in normal and Hyp-mouse osteoblasts and HYP patient-serum. 2. Determination of MEPE ASARM-peptide effects on mineralization in-vitro and in-vivo (rats). The ASARM-motif is present in a number of tooth-bone matrix and salivary proteins (MEPE, dentin-matrix-protein-1, osteopontin, statherin, dentin-sialo-phosphoprotein, etc.) that all map to chromosome 4q21. Thus, the elucidation of its role in mineralization is of prime importance for understanding tooth and bone development. Importantly, the part the motif plays in the multiple functions of MEPE will have relevance to the treatment and understanding of periodontal disease, oncogenic hypophosphatemic osteomalacia (OHO), HYP, osteoporosis and disorders of mineralization in teeth, bone, renal-stones and arteries.
描述(由申请人提供):x连锁低磷血症佝偻病(HYP)与肾脏磷酸盐处理、维生素D代谢和矿化的严重缺陷有关。了解骨矿物质/肾丢失疾病的病理生理学是有效治疗HYP、牙周病、肿瘤性骨软化、肾结石、骨质疏松、异位钙化和肾功能障碍的先决条件。我们有大量的初步数据支持这样的假设,即牙齿和骨骼中的矿化是由MEPE (HYP中基质细胞外磷酸糖蛋白显著升高)和PHEX (HYP中锌金属内肽酶缺陷)之间的蛋白质相互作用调节的。MEPE- phex蛋白相互作用保护MEPE免受HYP中显著升高的蛋白酶(特别是组织蛋白酶B)的蛋白水解裂解。在缺乏PHEX的情况下,成骨细胞和成牙细胞分泌的mepe被蛋白水解裂解,释放出磷酸化的、富含酸性天冬氨酸的、cooh末端的mepe片段(asarm肽)。asarm -肽(2 kDa)对大量导致Hyp水平升高的蛋白酶具有显著的抗性。asarm -肽抑制矿化,是正常矿化的负调节因子,asarm -肽的升高是Hyp矿化缺陷的全部或部分原因。本研究将特别关注MEPE和asarm -肽在疾病和健康矿化中的作用。我们的具体目标是:1。体外和体内正常、hypp小鼠成骨细胞及hypp患者血清中MEPE asarm肽的结构表征和定量。2. MEPE asarm肽对矿化作用的体外和体内(大鼠)测定。ASARM-motif存在于许多牙齿-骨基质和唾液蛋白(MEPE、牙本质基质蛋白-1、骨桥蛋白、牙本质-唾液磷酸化蛋白等)中,这些蛋白都位于染色体4q21上。因此,阐明其在矿化中的作用对于理解牙齿和骨骼的发育至关重要。重要的是,该基序在MEPE的多种功能中所起的作用将与牙周病、致癌性低磷性骨软化症(OHO)、HYP、骨质疏松症和牙齿、骨骼、肾结石和动脉矿化障碍的治疗和理解相关。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PETER S ROWE其他文献

PETER S ROWE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PETER S ROWE', 18)}}的其他基金

The Molecular Pathology and Etiology of Nephrogenic Systemic Fibrosis
肾源性系统纤维化的分子病理学和病因学
  • 批准号:
    9384115
  • 财政年份:
    2017
  • 资助金额:
    $ 2.63万
  • 项目类别:
Mineralization of the matrix in disease and health
疾病和健康中基质的矿化
  • 批准号:
    6830580
  • 财政年份:
    2004
  • 资助金额:
    $ 2.63万
  • 项目类别:
Mineralization of the matrix in disease and health
疾病和健康中基质的矿化
  • 批准号:
    8289459
  • 财政年份:
    2004
  • 资助金额:
    $ 2.63万
  • 项目类别:
Mineralization and the Role of Matrixphosphoglycoprotein
基质磷酸糖蛋白的矿化和作用
  • 批准号:
    6789566
  • 财政年份:
    2004
  • 资助金额:
    $ 2.63万
  • 项目类别:
Mineralization of the matrix in disease and health
疾病和健康中基质的矿化
  • 批准号:
    7146933
  • 财政年份:
    2004
  • 资助金额:
    $ 2.63万
  • 项目类别:
Mineralization of the matrix in disease and health
疾病和健康中基质的矿化
  • 批准号:
    7736587
  • 财政年份:
    2004
  • 资助金额:
    $ 2.63万
  • 项目类别:
Mineralization of the matrix in disease and health
疾病和健康中基质的矿化
  • 批准号:
    8097964
  • 财政年份:
    2004
  • 资助金额:
    $ 2.63万
  • 项目类别:
Mineralization of the matrix in disease and health
疾病和健康中基质的矿化
  • 批准号:
    6947829
  • 财政年份:
    2004
  • 资助金额:
    $ 2.63万
  • 项目类别:
Mineralization of the matrix in disease and health
疾病和健康中基质的矿化
  • 批准号:
    7088784
  • 财政年份:
    2004
  • 资助金额:
    $ 2.63万
  • 项目类别:
Mineralization of the matrix in disease and health
疾病和健康中基质的矿化
  • 批准号:
    7886611
  • 财政年份:
    2004
  • 资助金额:
    $ 2.63万
  • 项目类别:

相似海外基金

FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
  • 批准号:
    EP/Y036395/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.63万
  • 项目类别:
    Research Grant
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 2.63万
  • 项目类别:
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
  • 批准号:
    10764456
  • 财政年份:
    2023
  • 资助金额:
    $ 2.63万
  • 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
  • 批准号:
    10743328
  • 财政年份:
    2023
  • 资助金额:
    $ 2.63万
  • 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
  • 批准号:
    10638813
  • 财政年份:
    2023
  • 资助金额:
    $ 2.63万
  • 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
  • 批准号:
    10828665
  • 财政年份:
    2023
  • 资助金额:
    $ 2.63万
  • 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
  • 批准号:
    10823828
  • 财政年份:
    2023
  • 资助金额:
    $ 2.63万
  • 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
  • 批准号:
    10721095
  • 财政年份:
    2023
  • 资助金额:
    $ 2.63万
  • 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
  • 批准号:
    10795328
  • 财政年份:
    2023
  • 资助金额:
    $ 2.63万
  • 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
  • 批准号:
    10828252
  • 财政年份:
    2023
  • 资助金额:
    $ 2.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了